• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1282225 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
3 h+ |0 A% g7 MNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 * k0 q" w5 ~" g0 f0 i2 b
+ Author Affiliations
" P; J) @) n- ]3 m" A- g2 d  x! ]
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan . r- m3 |! u8 Z( m2 Y
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3 L1 b; I/ D2 ]& V0 P  |, j8 u, D3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan # c9 N+ n2 t  @* R- N& O
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan - v: g  j! |4 L/ H" W
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ' Y8 N) j( @9 o6 @
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
6 T9 I+ t1 N* i1 V7Kinki University School of Medicine, Osaka 589-8511, Japan
, j- ]( @% h' g& R( V8Izumi Municipal Hospital, Osaka 594-0071, Japan 5 T$ ]  X& a# N
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
' m1 F( F3 |- w$ SCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
3 C# A- k, k! T4 X) Q0 i* j! eAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
+ T3 y- ?+ w( g6 u) h
# s2 i0 \- y. r0 {3 ?
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type / g, h7 r7 x/ i  S+ E5 L( e( s

1 J. W0 |' D( v( GAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
4 C  e5 G8 {- T9 D7 h5 V+ Q4 g0 O% g6 p
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  1 B' r* v; p& R1 H

! p" Z+ u0 |1 g+ IPublished online on: Thursday, December 1, 2011 : I: G, G$ E& G! O

5 u+ `% t/ U9 dDoi: 10.3892/ol.2011.507 . @  J2 r1 A* ~6 ], J) j3 d
4 {$ g9 |+ ?. y6 C
Pages: 405-410
1 G" p2 M- S% m3 W
8 Z$ n7 J" R- \/ n  I, _1 bAbstract:6 _3 y! t0 t. M5 O: q9 z
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
' k* X+ C. G/ C6 @! g. x . z6 j; v- z% r; f
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
6 W, Z- z" X8 m0 A1 ]; S$ a0 lF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
2 T2 M- T9 {/ F- E* y' {+ Author Affiliations7 v' ]& E6 j1 g' j
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu ' ?! K2 |  s# V1 O, V
2Department of Thoracic Surgery, Kyoto University, Kyoto
5 E: g# `) f" B* z2 a, @! P& M+ ~+ O3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan * X2 e0 E$ e. @- g
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 4 D# u' C0 E) z6 Y
Received September 3, 2010. : {2 G0 o) Z+ w+ Z! r6 W
Revision received November 11, 2010. 7 r' Y2 R# [& U
Accepted November 17, 2010.
  U5 r% Q" z6 G& Y- y9 b1 cAbstract
5 _8 t- s" o4 Y$ c, Q! ]% g( B; d& IBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
  E% E* V5 a8 x3 ?7 ^' U! g; c, W0 HPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
! ?* N8 ]) E! f; d6 E2 \Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
( X0 X: D0 S. b6 z  g; w- qConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. - U0 }" E9 g3 \4 f6 N3 K* p2 Y
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。) ?# [& h: {+ x) H6 i8 a
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
8 I# _7 T% {( h) I, C6 h
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
- A# D& ]. j+ }& N8 ^! Jhttp://clinicaltrials.gov/ct2/show/NCT01523587
" P0 e( p% ]- A8 Q, d( T, w7 k9 A' v8 F& F4 H' |; F+ B$ }2 V( i
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC$ X  a* M3 A: J+ q3 _
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
) \* e) ~$ N% k1 S: p  d7 @; R9 E! b! P5 J! v4 b( Y
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
. D& C- d- d) v1 d. J5 y0 {至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
1 i# i! X+ x) b! d; k从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
9 G( f: G5 x/ [6 Y5 m+ z至今为止,未出 ...
. \! `. J6 Z3 f' y
没有副作用是第一追求,效果显著是第二追求。
6 _8 T# q" N0 Y不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表